急性病内科患者使用抗凝剂的干预试验：一个方法学上的陷阱？ - Suppr

Suppr

超能文献

Interventional trials with anticoagulants in acutely ill medical patients: a methodological pitfall?

作者信息

Violi Francesco, Perri Ludovica, Loffredo Lorenzo

机构信息

I Clinica Medica, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.

出版信息

Intern Emerg Med. 2013 Sep;8(6):461-4. doi: 10.1007/s11739-013-0970-6. Epub 2013 Jun 16.

DOI:10.1007/s11739-013-0970-6

PMID:23771271

Abstract

摘要

相似文献

Interventional trials with anticoagulants in acutely ill medical patients: a methodological pitfall?

Intern Emerg Med. 2013 Sep;8(6):461-4. doi: 10.1007/s11739-013-0970-6. Epub 2013 Jun 16.

Should all acutely ill medical patients be treated with antithrombotic drugs? A review of the interventional trials.

Thromb Haemost. 2013 Apr;109(4):589-95. doi: 10.1160/TH12-11-0860. Epub 2013 Feb 21.

Prevention of venous thromboembolism in hospitalized acutely ill medical patients: focus on the clinical utility of (low-dose) fondaparinux.

Drug Des Devel Ther. 2013 Sep 16;7:973-80. doi: 10.2147/DDDT.S38042. eCollection 2013.

Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients.

Thromb Haemost. 2012 Jun;107(6):1027-34. doi: 10.1160/TH11-11-0787. Epub 2012 Mar 22.

Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial).

Circulation. 2018 Jan 2;137(1):91-94. doi: 10.1161/CIRCULATIONAHA.117.031187.

Rivaroxaban for thromboprophylaxis in acutely ill medical patients.

N Engl J Med. 2013 May 16;368(20):1945-6. doi: 10.1056/NEJMc1303641.

Rivaroxaban for thromboprophylaxis in acutely ill medical patients.

N Engl J Med. 2013 May 16;368(20):1944-5. doi: 10.1056/NEJMc1303641.

Rivaroxaban for thromboprophylaxis in acutely ill medical patients.

N Engl J Med. 2013 May 16;368(20):1945. doi: 10.1056/NEJMc1303641.

Rivaroxaban for thromboprophylaxis in acutely ill medical patients.

N Engl J Med. 2013 May 16;368(20):1945. doi: 10.1056/NEJMc1303641.

Prevention of venous thromboembolism in acutely ill medical patients after the results of recent trials with the new oral anticoagulants.

Intern Emerg Med. 2013 Dec;8(8):667-72. doi: 10.1007/s11739-013-0979-x. Epub 2013 Jul 16.

引用本文的文献

Prophylaxis of venous thromboembolism in Internal Medicine Units: the RAMs issue.

Intern Emerg Med. 2018 Jun;13(4):463-465. doi: 10.1007/s11739-018-1829-7. Epub 2018 Mar 14.

Clinical impact of application of risk assessment models (Padua Prediction Score and Improve Bleeding Score) on venous thromboembolism, major hemorrhage and health expenditure associated with pharmacologic VTE prophylaxis: a "real life" prospective and retrospective observational study on patients hospitalized in a Single Internal Medicine Unit (the STIME study).

Intern Emerg Med. 2018 Jun;13(4):527-534. doi: 10.1007/s11739-018-1808-z. Epub 2018 Mar 3.

New oral anticoagulants for the treatment of acute venous thromboembolism: are they safer than vitamin K antagonists? A meta-analysis of the interventional trials.

Intern Emerg Med. 2015 Jun;10(4):499-506. doi: 10.1007/s11739-014-1171-7. Epub 2014 Dec 25.

Prophylaxis of venous thromboembolism in elderly patients with multi-morbidity: the REPOSI data.

Intern Emerg Med. 2015 Mar;10(2):251-2. doi: 10.1007/s11739-014-1103-6. Epub 2014 Oct 11.

本文引用的文献

Prophylaxis of venous thromboembolism in elderly patients with multimorbidity.

Intern Emerg Med. 2013 Sep;8(6):509-20. doi: 10.1007/s11739-013-0944-8. Epub 2013 May 8.

Should all acutely ill medical patients be treated with antithrombotic drugs? A review of the interventional trials.

Thromb Haemost. 2013 Apr;109(4):589-95. doi: 10.1160/TH12-11-0860. Epub 2013 Feb 21.

Rivaroxaban for thromboprophylaxis in acutely ill medical patients.

N Engl J Med. 2013 Feb 7;368(6):513-23. doi: 10.1056/NEJMoa1111096.

Do medical patients need to receive pharmacologic prophylaxis for the prevention of venous thromboembolism?

Intern Emerg Med. 2012 Oct;7 Suppl 3:S189-92. doi: 10.1007/s11739-012-0800-2.

Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Chest. 2012 Feb;141(2 Suppl):e195S-e226S. doi: 10.1378/chest.11-2296.

Low-molecular-weight heparin and mortality in acutely ill medical patients.

N Engl J Med. 2011 Dec 29;365(26):2463-72. doi: 10.1056/NEJMoa1111288.

A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score.

J Thromb Haemost. 2010 Nov;8(11):2450-7. doi: 10.1111/j.1538-7836.2010.04044.x.

Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial.

Ann Intern Med. 2010 Jul 6;153(1):8-18. doi: 10.7326/0003-4819-153-1-201007060-00004.

Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Chest. 2008 Jun;133(6 Suppl):381S-453S. doi: 10.1378/chest.08-0656.

Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial.

BMJ. 2006 Feb 11;332(7537):325-9. doi: 10.1136/bmj.38733.466748.7C. Epub 2006 Jan 26.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验